3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
CNS
4
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
Tumor-Agnostic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
lutetium Lu 177 dotatate
13
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Everolimus
8
cabozantinib
6
pembrolizumab
5
Nivolumab
4
olaparib
3
lenvatinib
3
X-Rays
3
Lutetium-177
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
Sunitinib
2
Radiotherapy
2
Phantoms, Imaging
2
Octreotide
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Etoposide
2
Cyclophosphamide
2
Cisplatin
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
telotristat ethyl
1
surufatinib
1
repotrectinib
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
entrectinib
×
NET
×
90 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA